Sector News

NPS Pharma asks Goldman Sachs to find a buyer: WSJ

January 6, 2015
Life sciences
Long cited as a takeover target, rare disease specialist NPS Pharmaceuticals is seeking a buyer, according to a report in the Wall Street Journal.
 
The newspaper reports that Goldman Sachs has started to contact companies to gauge their interest in NPS, which may be available at upwards of $4.5 billion. Shire has regularly been mentioned as a potential purchaser and is on the look-out for acquisitions having had its warchest boosted by a $1.6 billion break-up fee banked after AbbVie pulled out of a proposed merger last year.
 
NPS currently markets Gattex/Revestive (teduglutide) for short bowel syndrome. It is also waiting to hear from the US Food and Administration about Natpara (recombinant human parathyroid hormone) for the treatment of hypoparathyroidism and a decision is expected by the end of this month.
 
By Kevin Grogan
 
Source: Pharma Times
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]